Li Jieqing, Hao Qiongyu, Cao Wei, Vadgama Jaydutt V, Wu Yong
Department of Breast Surgery, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China.
Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles,CA, USA,
Cancer Manag Res. 2018 Oct 26;10:4653-4667. doi: 10.2147/CMAR.S178567. eCollection 2018.
Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively associated with the reduced risk of the occurrence and progression of a number of types of cancer, particularly breast cancer. This observation is also substantiated by various meta-analyses. Clinical trials have been implemented on integration treatment of celecoxib and shown encouraging results. Celecoxib could be treated as a potential candidate for antitumor agent. There are, nonetheless, some unaddressed questions concerning the precise mechanism underlying the anticancer effect of celecoxib as well as its activity against different types of cancer. In this review, we discuss different mechanisms of anticancer effect of celecoxib as well as preclinical/clinical results signifying this beneficial effect.
乳腺癌在全球范围内发病率很高。大量研究结果表明，炎症在许多恶性肿瘤的发生、发展和侵袭性中起着重要作用。新型非甾体抗炎药塞来昔布的使用反复与多种类型癌症（尤其是乳腺癌）发生和进展风险的降低相关。各种荟萃分析也证实了这一观察结果。已经开展了关于塞来昔布联合治疗的临床试验，并显示出令人鼓舞的结果。塞来昔布可被视为一种潜在的抗肿瘤药物候选物。然而，关于塞来昔布抗癌作用的确切机制及其对不同类型癌症的活性仍存在一些未解决的问题。在本综述中，我们讨论了塞来昔布抗癌作用的不同机制以及表明这种有益作用的临床前/临床结果。
